CA2611106A1 - Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus - Google Patents

Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus Download PDF

Info

Publication number
CA2611106A1
CA2611106A1 CA002611106A CA2611106A CA2611106A1 CA 2611106 A1 CA2611106 A1 CA 2611106A1 CA 002611106 A CA002611106 A CA 002611106A CA 2611106 A CA2611106 A CA 2611106A CA 2611106 A1 CA2611106 A1 CA 2611106A1
Authority
CA
Canada
Prior art keywords
protein
coronavirus
cellular
sars
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002611106A
Other languages
English (en)
Inventor
Beatrice Therese Marie Nal-Rogier
Ralf Marius Altmeyer
Francois Kien
Jean Millet
Kim Tat Teoh
Yu Lam Siu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pasteur Research Center HKU
Original Assignee
Pasteur Research Center HKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002569080A external-priority patent/CA2569080A1/fr
Application filed by Pasteur Research Center HKU filed Critical Pasteur Research Center HKU
Priority to CA002611106A priority Critical patent/CA2611106A1/fr
Publication of CA2611106A1 publication Critical patent/CA2611106A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002611106A 2006-11-20 2007-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus Abandoned CA2611106A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002611106A CA2611106A1 (fr) 2006-11-20 2007-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002569080A CA2569080A1 (fr) 2006-11-20 2006-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus
CA2,569,080 2006-11-20
CA002611106A CA2611106A1 (fr) 2006-11-20 2007-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus

Publications (1)

Publication Number Publication Date
CA2611106A1 true CA2611106A1 (fr) 2008-05-20

Family

ID=39420445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002611106A Abandoned CA2611106A1 (fr) 2006-11-20 2007-11-20 Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus

Country Status (1)

Country Link
CA (1) CA2611106A1 (fr)

Similar Documents

Publication Publication Date Title
Xie et al. Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID‐19 therapy
Nagashima et al. Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions
Knegendorf et al. Hepatitis E virus replication and interferon responses in human placental cells
RU2503686C2 (ru) Новые противовирусные пептиды, которые предотвращают связывание вируса с dlc8
Yang et al. Annexin 2 is a host protein binding to classical swine fever virus E2 glycoprotein and promoting viral growth in PK-15 cells
US7632801B2 (en) Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
Yang et al. Drug repurposing of itraconazole and estradiol benzoate against COVID‐19 by blocking SARS‐CoV‐2 spike protein‐mediated membrane fusion
Bhuvanakantham et al. Human Sec3 protein is a novel transcriptional and translational repressor of flavivirus
Guo et al. Identification of a new region of SARS-CoV S protein critical for viral entry
WO2021239086A1 (fr) Pseudovirus du sras-cov-2 et méthode pour tester la capacité d'un échantillon à neutraliser le sras-cov-2
WO2008062309A2 (fr) Molécules anti-coronavirus et leur utilisation dans des compositions et procédés pour traiter et/ou prévenir une infection provoquée par un coronavirus
WO2007005244A1 (fr) Recepteur de l'henipavirus et ses utilisations
US9297798B2 (en) Therapeutic approach for polyglutamine degeneration
DK1981904T3 (en) Peptide domain from the enclosure of a HERV-W virus, which is required for reaction with a hASCT receptor
Essalmani et al. Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2’by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2
CA2611106A1 (fr) Molecules anti-coronavirus et leur utilisation dans les compositions, et methodes de traitement et/ou prevention de l'infection causee par un coronavirus
US7494780B2 (en) Epididymis-specific defensin for evaluating and regulating male fertility
Simmons et al. Proteolysis of SARS-associated coronavirus spike glycoprotein
EP1880212A2 (fr) Methodes et compositions servant a inhiber l'infection vih utilisant d'agents qui modulent isopeptidase t
Moriuchi et al. Long‐term expression of the lamin A mutant associated with dilated cardiomyopathy induces senescence
US10883980B2 (en) Methods and compositions for inhibiting hepatitis E virus
Wang et al. GB virus type C E2 protein inhibits human immunodeficiency virus type 1 gag assembly by downregulating human ADP-ribosylation factor 1
Ding et al. Hrs inhibits citron kinase-mediated HIV-1 budding via its FYVE domain
CN102453712B (zh) PI4KB siRNA及其在制备抑制SARS-CoV感染的药物中的用途
Cuesta-Geijo et al. Endosomal proteins NPC1 and NPC2 at African swine fever virus entry/fusion

Legal Events

Date Code Title Description
FZDE Dead